Entrada Therapeutics Q2 EPS $(1.04) Misses $(0.85) Estimate, Sales $1.950M Miss $9.651M Estimate
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.85) by 22.64 percent. This is a 167.1 percent decrease over earnings of $1.55 per share
